375 related articles for article (PubMed ID: 23843441)
1. Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial.
Brasky TM; Darke AK; Song X; Tangen CM; Goodman PJ; Thompson IM; Meyskens FL; Goodman GE; Minasian LM; Parnes HL; Klein EA; Kristal AR
J Natl Cancer Inst; 2013 Aug; 105(15):1132-41. PubMed ID: 23843441
[TBL] [Abstract][Full Text] [Related]
2. Serum phospholipid fatty acids and prostate cancer risk: results from the prostate cancer prevention trial.
Brasky TM; Till C; White E; Neuhouser ML; Song X; Goodman P; Thompson IM; King IB; Albanes D; Kristal AR
Am J Epidemiol; 2011 Jun; 173(12):1429-39. PubMed ID: 21518693
[TBL] [Abstract][Full Text] [Related]
3. Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk.
Kristal AR; Darke AK; Morris JS; Tangen CM; Goodman PJ; Thompson IM; Meyskens FL; Goodman GE; Minasian LM; Parnes HL; Lippman SM; Klein EA
J Natl Cancer Inst; 2014 Mar; 106(3):djt456. PubMed ID: 24563519
[TBL] [Abstract][Full Text] [Related]
4. Associations of erythrocyte ω-3 fatty acids with biomarkers of ω-3 fatty acids and inflammation in breast tissue.
Roy S; Brasky TM; Belury MA; Krishnan S; Cole RM; Marian C; Yee LD; Llanos AA; Freudenheim JL; Shields PG
Int J Cancer; 2015 Dec; 137(12):2934-46. PubMed ID: 26137879
[TBL] [Abstract][Full Text] [Related]
5. Meta-Analysis of Long-Chain Omega-3 Polyunsaturated Fatty Acids (LCω-3PUFA) and Prostate Cancer.
Alexander DD; Bassett JK; Weed DL; Barrett EC; Watson H; Harris W
Nutr Cancer; 2015; 67(4):543-54. PubMed ID: 25826711
[TBL] [Abstract][Full Text] [Related]
6. Fatty acid patterns and risk of prostate cancer in a case-control study nested within the European Prospective Investigation into Cancer and Nutrition.
Dahm CC; Gorst-Rasmussen A; Crowe FL; Roswall N; Tjønneland A; Drogan D; Boeing H; Teucher B; Kaaks R; Adarakis G; Zylis D; Trichopoulou A; Fedirko V; Chajes V; Jenab M; Palli D; Pala V; Tumino R; Ricceri F; van Kranen H; Bueno-de-Mesquita HB; Quirós JR; Sánchez MJ; Luján-Barroso L; Larrañaga N; Chirlaque MD; Ardanaz E; Johansson M; Stattin P; Khaw KT; Wareham N; Wark PA; Norat T; Riboli E; Key TJ; Overvad K
Am J Clin Nutr; 2012 Dec; 96(6):1354-61. PubMed ID: 23134890
[TBL] [Abstract][Full Text] [Related]
7. RE: Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial.
Tokudome S; Ando R; Ichikawa Y; Ichikawa H; Imaeda N; Goto C; Tokudome Y; Okuyama H
J Natl Cancer Inst; 2014 Apr; 106(4):dju020. PubMed ID: 24685933
[No Abstract] [Full Text] [Related]
8. RE: Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial.
Cleland LG; Proudman SM; James MJ
J Natl Cancer Inst; 2014 Apr; 106(4):dju022. PubMed ID: 24685932
[No Abstract] [Full Text] [Related]
9. RE: Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial.
McCarty MF; Dinicolantonio JJ; Lavie CJ; O'Keefe JH
J Natl Cancer Inst; 2014 Apr; 106(4):dju014. PubMed ID: 24685931
[No Abstract] [Full Text] [Related]
10. RE: Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial.
Torfadottir JE; Stampfer MJ; Mucci LA; Giovannucci EL
J Natl Cancer Inst; 2014 Apr; 106(4):dju018. PubMed ID: 24685929
[No Abstract] [Full Text] [Related]
11. RE: Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial.
Harris WS; Davidson MH
J Natl Cancer Inst; 2014 Apr; 106(4):dju019. PubMed ID: 24685928
[No Abstract] [Full Text] [Related]
12. RE: Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial.
Brenna JT; Burdge GC; Crawford MA; Clayton P; Cunnane SC; Gow R; Hibbeln JR; Sinclair AJ; Stein J; Willatts P
J Natl Cancer Inst; 2014 Apr; 106(4):dju015. PubMed ID: 24685922
[No Abstract] [Full Text] [Related]
13. RE: Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial.
El-Bayoumy K; Thompson H; Manni A
J Natl Cancer Inst; 2014 Apr; 106(4):dju017. PubMed ID: 24685921
[No Abstract] [Full Text] [Related]
14. Re: plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial.
Taneja SS
J Urol; 2014 Mar; 191(3):658. PubMed ID: 24522035
[No Abstract] [Full Text] [Related]
15. Prediagnostic level of fatty acids in serum phospholipids: omega-3 and omega-6 fatty acids and the risk of prostate cancer.
Harvei S; Bjerve KS; Tretli S; Jellum E; Robsahm TE; Vatten L
Int J Cancer; 1997 May; 71(4):545-51. PubMed ID: 9178806
[TBL] [Abstract][Full Text] [Related]
16. Words of wisdom: Re: Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial.
Sosnowski R; Zawistowski J
Eur Urol; 2014 May; 65(5):1012. PubMed ID: 24646497
[No Abstract] [Full Text] [Related]
17. Words of wisdom. Re: Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial.
Chow K; Murphy DG
Eur Urol; 2013 Dec; 64(6):1015-6. PubMed ID: 24209450
[No Abstract] [Full Text] [Related]
18. RE: Serum phospholipid fatty acids and prostate cancer risk in the SELECT trial.
McCulloch M; Alvarez E; Gendreau R; Haney S; Harrelson J; Luo R
J Natl Cancer Inst; 2014 Apr; 106(4):dju024. PubMed ID: 24685926
[No Abstract] [Full Text] [Related]
19. RE: Serum phospholipid fatty acids and prostate cancer risk in the SELECT trial.
Suburu J; Lim K; Calviello G; Chen YQ
J Natl Cancer Inst; 2014 Apr; 106(4):dju023. PubMed ID: 24685923
[No Abstract] [Full Text] [Related]
20. Difference in Association of Obesity With Prostate Cancer Risk Between US African American and Non-Hispanic White Men in the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
Barrington WE; Schenk JM; Etzioni R; Arnold KB; Neuhouser ML; Thompson IM; Lucia MS; Kristal AR
JAMA Oncol; 2015 Jun; 1(3):342-9. PubMed ID: 26181184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
